Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
about
Effects of nilotinib on regulatory T cells: the dose mattersRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedUpdate on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibCardiac effects of anticancer therapy in the elderlyResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsOnce-daily dasatinib for treatment of patients with chronic myeloid leukemia.Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibExpanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phaseNilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.Emerging drugs for chronic myeloid leukemia.Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinibBortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluidFailure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blastPractical management of patients with chronic myeloid leukemia.Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibPruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisResults of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaChronic myelogenous leukemia: treatment and monitoring.Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.Cytogenetic study in CML.Clinical cardiac safety profile of nilotinib.Suboptimal responses in chronic myeloid leukemia: implications and management strategiesA coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemiaManaging chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersNilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patientsSuboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
P2860
Q21245709-8BA29CC3-77A0-48A4-9F27-50364AEC0B7FQ26738514-9204C79E-2BD9-43EC-9ADD-1590E15930E5Q26751285-7601C811-4E33-4FC5-B9F6-5155A37B81D9Q26863244-F68BE6DC-D866-42AC-9931-9888CB8BCAE1Q27028181-88775C5B-EEA4-43A8-9D1F-8DBA92EBA9DCQ33383954-B27BC5FE-930A-42CF-919E-9BD3FF303EAEQ33394812-9696D7AB-A2DE-4984-A515-63ECBB8D7236Q33396120-C1F758F2-473B-4D2D-B309-FB521C09B9B1Q33398183-A7840C2A-6F49-4FF0-853C-56D67BA00E72Q33398485-82C842B9-63F0-4BCB-B923-16CB5BE02FEBQ33399867-E2623D51-6B13-42D7-91F7-E4E05F12BD9CQ33518973-70F065B4-FD04-42C6-94C4-5DFA4B2BB001Q33536762-4F8FA535-CA9D-4AC9-B155-863BD80FEDFCQ33707394-AE6E0AD7-38CC-4876-90A2-642E7B676729Q33747277-226DC734-CC43-4563-9EFC-D541C65813AAQ33841347-ABDBEF39-7FFF-4C9F-8790-3BFF63E7990AQ33844007-A841BF77-CD68-4B4C-A466-53D941F962BBQ33849146-ED1E7711-7C4E-46E7-9BE2-A2ED2FC7D283Q33926222-810CFFCB-956E-434C-9747-92C930162912Q34099289-73BD6E73-3475-432C-A340-B91750E9854FQ34166538-64F13C96-44CD-47C5-94FE-3A9F51C5F249Q34210528-13066B3B-D807-499B-A9C2-FA257077CAFEQ34272887-003C1F15-5D17-408B-ADAE-1D8225B139E0Q34293414-C5570F40-5550-4FC2-8B94-7EBE47E388DBQ34480473-A1CA0346-A4D8-42AE-9795-915501C1EBA9Q34522789-300A4B50-B47F-475A-AA46-6A8F9BFB13E9Q34617628-63F20865-8865-46AE-B1B0-C9CB5BA1AC16Q34894883-310AF15D-08AA-45A7-9450-09A393C9D229Q35510549-6F69A358-CC7B-40E2-A3F6-2EAC5D23D5B7Q35838636-20F462A4-7DF9-48FD-97C5-972DFAE387AFQ36006389-C0B0FD7F-444F-49B7-AEDE-4C53782A9D1CQ36144079-745F1DC0-BED1-41D0-8B1E-481E91C3148AQ36210636-FBC01492-9A42-4E40-885B-8BCCA0BBF577Q36355098-15B4E26C-8F12-4D17-AC7C-119E359474C2Q36374813-D711833F-D084-48E6-BB69-007020808EDAQ37026026-86B4BA4F-F5DF-47F7-A1B7-D47E7E7D1C4AQ37082725-B2CEC610-863F-4C29-A02C-5D577E278578Q37098747-5B869F28-6662-4285-8DB5-EA1FA548A208Q37139374-1FCBBBF1-3704-47F8-9B1E-92FDB3741839Q37148391-5E626CB5-F1C5-4DDE-BE6A-144558F9E07A
P2860
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Nilotinib (formerly AMN107), a ...... chronic myelogenous leukemia.
@ast
Nilotinib (formerly AMN107), a ...... chronic myelogenous leukemia.
@en
type
label
Nilotinib (formerly AMN107), a ...... chronic myelogenous leukemia.
@ast
Nilotinib (formerly AMN107), a ...... chronic myelogenous leukemia.
@en
prefLabel
Nilotinib (formerly AMN107), a ...... chronic myelogenous leukemia.
@ast
Nilotinib (formerly AMN107), a ...... chronic myelogenous leukemia.
@en
P2093
P50
P1433
P1476
Nilotinib (formerly AMN107), a ...... chronic myelogenous leukemia.
@en
P2093
Dong-Wook Kim
Francois-Xavier Mahon
Jane F Apperley
Jerald P Radich
Kazimierz Kuliczkowski
Marco Gobbi
Ming Zheng
Philipp le Coutre
Stephen G O'Brien
Timothy Hughes
P304
P356
10.1182/BLOOD-2007-04-083196
P407
P50
P577
2007-11-29T00:00:00Z